Literature DB >> 11819763

Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab')(2) fragment and staphylococcal enterotoxin A.

L J Yang1, Y F Sui, Z N Chen.   

Abstract

AIM: To prepare the conjugate of staphylococcal enterotoxin A (SEA) protein which is a bacterial SAg and the F(ab')(2) fragment of mAb HAb18 against human hepatocellular carcinoma (HCC), and identify its activity in order to use SAg in the targeting therapy of HCC.
METHODS: MAb HAb18 was extracted from the abdominal dropsy of Balb/c mice, and was purified through chromatography column SP 40HR with Fast protein liquid chromatography (FPLC) system. The F(ab')(2) fragment of mAb HAb18 was prepared by papainic digestion method. The conjugate of mAb HAb18 F(ab')(2) fragment and SEA was prepared with chemical conjugating reagent N succinimidyl 3 (2-pyridyldithio) propionate (SPDP) and purified through chromatography column Superose 12 with FPLC system. The molecular mass and purity of each collected peak were identified with SDS-PAGE assay. The protein content was assayed by Lowry's method. The antibody activity of HAb18 F(ab')(2) against HCC in the conjugate was identified by indirect immunocytochemical ABC method, and the activity of SEA in the conjugate to activate peripheral blood mononuclear cells (PBMC) was identified with MTT assay.
RESULTS: The IgG mAb HAb18 was extracted, and purified successfully. Immunocytochemical staining demonstrated that it reacted with most of HHCC cells of human HCC cell line. There were two peaks in the process of purification of the prepared HAb18 F(ab')(2) SEA conjugate. SDS-PAGE assay demonstrated that the molecular mass of the first peak was about 130 ku, and the second peak was the mixture of about 45 ku and a little 100 ku proteins. The immunocytochemical staining was similar in HAb18 F(ab') (2) SEA conjugate and HAb18 F(ab') (2), i.e.the cytoplasm and/or cell membranes of most HHCC cells were positively stained. The MTT assay showed that the optical absorbance (A) value at 490 nm of HAb18 F(ab') (2) SEA conjugate was 0.182 +/- 0.012, that of negative control was 0.033 +/- 0.009, and there was significant difference between them (P < 0.05).
CONCLUSION: SPDP is a good protein conjugating reagent and can be used in preparing protein conjugate. The conjugate of mAb HAb18 F(ab') (2) fragment and SEA protein was prepared successfully in present study and can be used in the experimental study of HCC targeting therapy with the conjugate of SAg and anti HCC mAbs or their fragments.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11819763      PMCID: PMC4723525          DOI: 10.3748/wjg.v7.i2.216

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

1.  Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-04-06       Impact factor: 15.470

Review 2.  Microbial superantigens: from structure to function.

Authors:  A C Papageorgiou; K R Acharya
Journal:  Trends Microbiol       Date:  2000-08       Impact factor: 17.079

3.  Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.

Authors:  C Gidlöf; M Dohlsten; T Kalland; T H Tötterman
Journal:  Leukemia       Date:  1995-09       Impact factor: 11.528

Review 4.  Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.

Authors:  J M Schlaeppi; J M Wood
Journal:  Cancer Metastasis Rev       Date:  1999       Impact factor: 9.264

5.  Tumor therapy with bispecific antibody: the targeting and triggering steps can be separated employing a CD2-based strategy.

Authors:  M K Wild; W Strittmatter; S Matzku; B Schraven; S C Meuer
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

6.  Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.

Authors:  R Stein; M Juweid; M J Mattes; D M Goldenberg
Journal:  Cancer Biother Radiopharm       Date:  1999-02       Impact factor: 3.099

7.  Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.

Authors:  A Rosendahl; K Kristensson; J Hansson; L Ohlsson; T Kalland; M Dohlsten
Journal:  Int J Cancer       Date:  1998-04-13       Impact factor: 7.396

8.  Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.

Authors:  M Dohlsten; L Abrahmsén; P Björk; P A Lando; G Hedlund; G Forsberg; T Brodin; N R Gascoigne; C Förberg; P Lind
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

9.  MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.

Authors:  D W Newton; M Dohlsten; P A Lando; T Kalland; C Olsson; M Kotb
Journal:  Int J Mol Med       Date:  1998-01       Impact factor: 4.101

10.  Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: a novel drug carrier for cancer targeting therapy.

Authors:  S Tsunoda; I Ohizumi; J Matsui; K Koizumi; Y Wakai; H Makimoto; Y Tsutsumi; N Utoguchi; K Taniguchi; H Saito; N Harada; Y Ohsugi; T Mayumi
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

View more
  8 in total

1.  Expression and bioactivity identification of soluble MG7 scFv.

Authors:  Zhao-Cai Yu; Jie Ding; Bo-Rong Pan; Dai-Ming Fan; Xue-Yong Zhang
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

2.  Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro.

Authors:  Yu Li; Peng Shang; Ai-Rong Qian; Li Wang; Yong Yang; Zhi-Nan Chen
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

3.  Aggregate formation of hepatitis B virus X protein affects cell cycle and apoptosis.

Authors:  Chang-Zheng Song; Zeng-Liang Bai; Chang-Cheng Song; Qing-Wei Wang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

4.  Preparation of monoclonal antibody against apoptosis-associated antigens of hepatoma cells by subtractive immunization.

Authors:  Lian-Jun Yang; Wen-Liang Wang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

5.  Expression and function of classical protein kinase C isoenzymes in gastric cancer cell line and its drug-resistant sublines.

Authors:  Ying Han; Zhe-Yi Han; Xin-Min Zhou; Ru Shi; Yue Zheng; Yong-Quan Shi; Ji-Yan Miao; Bo-Rong Pan; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

6.  Pharmacokinetics of radioimmunotherapeutic agent of direct labeling mAb 188Re-HAb18.

Authors:  Chao Lou; Zhi-Nan Chen; Hui-Jie Bian; Jie Li; Shou-Bo Zhou
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

Review 7.  Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2014-03-28

8.  Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine.

Authors:  Yan Guo; Xi'an Li; Xiang Sun; Jiancai Wang; Xu Yang; Xin Zhou; Xinping Liu; Wenchao Liu; Jianlin Yuan; Libo Yao; Xia Li; Lan Shen
Journal:  Int J Biol Sci       Date:  2019-07-03       Impact factor: 6.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.